Drug updated on 5/17/2024
Dosage Form | Capsule (oral; 200 mg); Injection (intravenous; 200mg/20 mL) |
Drug Class | Orthopoxvirus VP37 envelope wrapping protein inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Tecovirimat (TPOXX) is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg and has also been explored for use against monkeypox.
- Five studies were reviewed which primarily compared tecovirimat with two other antivirals: brincidofovir and cidofovir.
- Tecovirimat emerged as the most prominently used and beneficial antiviral in the treatment of monkeypox, showing a high report of symptom resolution without major safety concerns according to these studies.
- Brincidofovir showed potential safety issues related to liver injury not associated with tecovirimat usage; it was less favorable due to adverse events leading to discontinuation. Cidofovir appears less commonly used possibly due to availability or side effect profile considerations.
- One study highlighted limited observational studies reporting uneventful treatment with tecovirimat in children and pregnant individuals, though conclusive data on safety or efficacy are inadequately represented within these subgroups.
- The studies concluded that while tecovirimat holds promise particularly when compared to other antiviral options, gaps exist necessitating cautious interpretation of findings until more robust clinical trials can conclusively establish its safety and effectiveness across all possible subgroups including children, pregnant women, those with severe disease or immunosuppression.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
TPOXX (tecovirimat) Prescribing Information. | 2022 | Siga Technologies Inc., Corvallis, OR |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Paediatric, maternal, and congenital mpox: a systematic review and meta-analysis. | 2024 | The Lancet. Global Health |
Therapeutics for treating mpox in humans. | 2023 | The Cochrane Database of Systematic Reviews |
The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review. | 2022 | International Journal of Infectious Diseases |
Clinical features, antiviral treatment, and patient outcomes: a systematic review and comparative analysis of the previous and the 2022 mpox outbreaks. | 2022 | Journal of Infectious Diseases |
Prevention and treatment of monkeypox: a systematic review of preclinical studies. | 2022 | Viruses |
Efficacy of three key antiviral drugs used to treat orthopoxvirus infections: a systematic review. | 2019 | Global Biosecurity |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Interim clinical treatment considerations for severe manifestations of Mpox - United States, February 2023. | 2023 | Morbidity and Mortality Weekly Report |